Is UGN up or down today?
UGN is down 0.29% today, last at 125.55. This stock moved -0.29% versus the prior close.
UGN · UGN
UGN (UGN) is trading at 125.55, down 0.29% on the session. UGN sits at the 50% mark of its 52-week range, carries a 14-day RSI of 35, and trades below its 50-day average. Over the past month it is down 7.96%.
Leading the coverage: “UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN) - simplywall.st” (Google News Company, 22d ago). UGN is +1.73% since story.
UGN trades on a trailing P/E of 15.1 and is running 6.90% behind the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
UGN is down 0.29% today, last at 125.55. This stock moved -0.29% versus the prior close.
Leading the coverage: “UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN) - simplywall.st” (Google News Company, 22d ago). UGN is +1.73% since story. Dominant story: UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN) - simplywall.st (1 source, neutral) RSI is 35 — leaning bearish Price below 50-day average — short-term weakness Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: Mar 2026 – Sep 2026 (181 days) · Drag or scroll left for earlier dates
UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN) - simplywall.st
NDA Is Submitted for UGN-103 for Recurrent Low-Grade Intermediate-Risk NMIBC - OncLive
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC - Yahoo Finance
FDA Clears IND For UGN-501 in Non-Muscle Invasive Bladder Cancer - CancerNetwork
Bladder Cancer Oncolytic Virus UGN-501 Cleared by FDA for Phase 1 Trials This Fall - Tech Times